Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 5/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 5/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7818166 | 0.82 | GRM2 (0.40) | GRM2HSD11B1PARP1NR1H2NR1H3 | |
| SCHEMBL18894119 | 0.79 | HSD11B1 (0.30) | HSD11B1 | |
| SCHEMBL1826324 | 0.78 | AURKA (0.35) | — | |
| SCHEMBL18894134 | 0.76 | — | — | |
| SCHEMBL18894169 | 0.76 | — | — | |
| SCHEMBL18894172 | 0.74 | — | — | |
| SCHEMBL3278279 | 0.68 | GRM2 (0.54) | GRM2HSD11B1PARP1CYP3A4CYP2D6 | |
| SCHEMBL27249457 | 0.66 | NR1H2 (0.44) | GRM2HSD11B1PARP1NR1H2NR1H3 | |
| SCHEMBL558259 | 0.65 | ATM (0.39) | CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL26375284 | 0.64 | CYP1A2 (0.47) | GRM2HSD11B1NR1H2NR1H3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136310-B2 | Iminotetrahydropyrimidinone derivatives as plasmepsin V inhibitors | UCB Biopharma SRL (BE) | 2021-10-05 | — | — | US | disclosed |
| US-20200283416-A1 | IMINOTETRAHYDROPYRIMIDINONE DERIVATIVES AS PLASMEPSIN V INHIBITORS | CELLTECH R&D LIMITED (GB) | 2020-09-10 | — | — | US | disclosed |
| EP-3380464-A1 | IMINOTETRAHYDROPYRIMIDINONE DERIVATIVES AS PLASMEPSIN V INHIBITORS | UCB Biopharma SPRL (BE) | 2018-10-03 | — | — | EP | disclosed |
| WO-2017089453-A1 | IMINOTETRAHYDROPYRIMIDINONE DERIVATIVES AS PLASMEPSIN V INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2017-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283416-A1 | IMINOTETRAHYDROPYRIMIDINONE DERIVATIVES AS PLASMEPSIN V INHIBITORS | PEPD, ADAM17, ANPEP | GRM2 3288/4885HSD11B1 3255/4885PARP1 680/4885 |
| US-11136310-B2 | Iminotetrahydropyrimidinone derivatives as plasmepsin V inhibitors | PEPD, ADAM17, ANPEP | GRM2 3288/4885HSD11B1 3255/4885PARP1 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.